NPIC
HRMY icon

Neumeier Poma Investment Counsel’s Harmony Biosciences HRMY Stock Holding History

Neumeier Poma Investment Counsel’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-595,490
Closed -$19.5M – 42
2023
Q3 		$19.5M Sell
595,490
-40,750
-6% -$1.41M 1.91% 25
2023
Q2 		$22.4M Sell
636,240
-42,475
-6% -$1.47M 2.05% 25
2023
Q1 		$22.2M Sell
678,715
-6,625
-1% -$302K 2.07% 23
2022
Q4 		$37.8M Buy
685,340
+48,855
+8% +$2.69M 3.51% 8
2022
Q3 		$28.2M Buy
636,485
+250,170
+65% +$12.2M 2.79% 15
2022
Q2 		$18.8M Buy
+386,315
New +$17.4M 1.47% 35

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Neumeier Poma Investment Counsel's HRMY Position: Q4 2023 in Review

Neumeier Poma Investment Counsel sold out of Harmony Biosciences (HRMY) in Q4 2023, closing a stake of 595,490 shares — an estimated $19.5M sold.

Neumeier Poma Investment Counsel first reported a position in HRMY in Q2 2022 and held it in 6 quarters. The position peaked at $37.8M in Q4 2022. 221 funds tracked by Wall St. Rank hold HRMY as of Q4 2023.

  • Neumeier Poma Investment Counsel reported no remaining Harmony Biosciences position as of Q4 2023 after selling out during the quarter.
  • Neumeier Poma Investment Counsel sold 595,490 Harmony Biosciences shares in Q4 2023, an estimated $19.5M.
  • Neumeier Poma Investment Counsel first reported a position in Harmony Biosciences in Q2 2022 and held it in 6 quarters.
  • Neumeier Poma Investment Counsel's Harmony Biosciences position peaked at $37.8M in Q4 2022.
  • 221 funds tracked by Wall St. Rank held Harmony Biosciences as of Q4 2023.

Based on Neumeier Poma Investment Counsel's 13F filing for Q4 2023, filed 13 Feb 2024.